80年代土耳其译制电影,80年代外国电影|80年代外国电影有哪些_80年代外国经典电影在线播放地址是多少？

[1]陳玲玲 吳梅梅 林偉國(guó) 鄭偉兵 朱 琪.瞬時(shí)彈性成像技術(shù)在肝纖維化及脂肪肝診斷中的作用[J].福建醫(yī)藥雜志,2020,42(02):29-32.
　CHEN Lingling,WU Meimei,LIN Weiguo,et al.Role of Fibroscan in the diagnosis of liver fibrosis and hepatic steatosis[J].FUJIAN MEDICAL JOURNAL,2020,42(02):29-32.
點(diǎn)擊復(fù)制

瞬時(shí)彈性成像技術(shù)在肝纖維化及脂肪肝診斷中的作用()
分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期數(shù):
2020年02期
頁(yè)碼:
29-32
欄目:
臨床研究
出版日期:
2020-04-15

文章信息/Info

Title:
Role of Fibroscan in the diagnosis of liver fibrosis and hepatic steatosis
文章編號(hào):
1002-2600(2020)02-0029-04
作者:
陳玲玲 吳梅梅 林偉國(guó) 鄭偉兵 朱 琪1
廈門大學(xué)附屬福州第二醫(yī)院肝膽內(nèi)科(福州 350007)
Author(s):
CHEN Lingling; WU Meimei; LIN Weiguo; ZHENG Weibing; ZHU Qi.
Department of Hepatobiliary Internal Medicine, Fuzhou Second Hospital Affiliated to Xiamen University,Fuzhou,Fujian 350007,China
關(guān)鍵詞:
瞬時(shí)彈性成像技術(shù);  肝硬化;  非酒精性脂肪肝;  肝纖維化;  肝脂肪變
Keywords:
fibroscan;  liver cirrhosis;  nonalcoholic fatty liver;  liver fibrosis;  hepatic steatosis
分類號(hào):
R575
文獻(xiàn)標(biāo)志碼:
A
摘要:
目的 分析瞬時(shí)彈性成像技術(shù)(Fibroscan)在肝纖維化及脂肪肝診斷中的作用。 方法 納入2014年9月至2017年9月初次就診廈門大學(xué)附屬福州第二醫(yī)院臨床診斷為乙肝表面抗原攜帶者、肝硬化代償期、非酒精性脂肪肝的患者為研究對(duì)象。每個(gè)研究對(duì)象均進(jìn)行1次Fibroscan檢測(cè)。以肝硬化患者為研究1組,乙肝表面抗原攜帶者為對(duì)照組,通過(guò)比較兩組間瞬時(shí)彈性測(cè)定值(E值)情況來(lái)判斷Fibroscan檢測(cè)肝纖維化程度的準(zhǔn)確率。以非酒精性脂肪肝患者為研究2組,乙肝表面抗原攜帶者為對(duì)照組,通過(guò)比較兩組間的肝脂肪受控衰減參數(shù)(CAP)值來(lái)判斷Fibroscan檢測(cè)肝脂肪變程度的準(zhǔn)確率。結(jié)果 研究1組共納入肝硬化患者83例,對(duì)照組納入乙肝表面抗原攜帶者1 026例。E值(kPa)以7.3為臨界值時(shí),研究1組與對(duì)照組間陽(yáng)性率差異有統(tǒng)計(jì)學(xué)意義(98.80% vs 29.73%,χ2=161.237,P=0.000); E以9.7為臨界值時(shí),兩組間陽(yáng)性率差異有統(tǒng)計(jì)學(xué)意義(98.80% vs 11.01%,χ2=408.303,P=0.000); E以12.4為臨界值,兩組間陽(yáng)性率差異有統(tǒng)計(jì)學(xué)意義(96.39% vs 4.87%,χ2=621.426,P=0.000); E以17.5為臨界值,兩組間陽(yáng)性率差異有統(tǒng)計(jì)學(xué)意義(93.98% vs 1.85%,χ2=816.490,P=0.000)。研究1組E值中位數(shù)為26.30 kPa,對(duì)照組E值中位數(shù)為6.10 kPa,兩組間平均值差異有統(tǒng)計(jì)學(xué)意義(P=0.000)。研究2組共納入非酒精性脂肪肝患者632例,對(duì)照組納入乙肝表面抗原攜帶者1 026例。以CAP值≥237.7 dB/m為陽(yáng)性,研究2組陽(yáng)性586例,陰性46例; 對(duì)照組陽(yáng)性325例,陰性701例。研究2組與對(duì)照組間陽(yáng)性率差異有統(tǒng)計(jì)學(xué)意義(92.72% vs 31.68%,χ2= 588.724,P=0.000)。研究2組CAP值的中位數(shù)為293 dB/m,對(duì)照組CAP值的中位數(shù)為212 dB/m,兩組間平均值差異有統(tǒng)計(jì)學(xué)意義(P=0.000)。 結(jié)論 Fibroscan在肝纖維化及脂肪肝診斷中具有重要價(jià)值。
Abstract:
Objective To analyze the role of Fibroscan in the diagnosis of liver fibrosis and hepatic steatosis.Methods The patients who were firstly diagnosed as hepatitis B surface antigen carriers, compensatory stage of liver cirrhosis and non-alcoholic fatty liver in Fuzhou Second Hospital Affiliated to Xiamen University from September 2014 to September 2017 were included in the study.The Fibroscan test was performed in each of the subjects.Patients with liver cirrhosis were taken as the study group one and carriers of hepatitis B surface antigen were taken as the control group.By comparing the instantaneous elasticity measurement(E value)between the two groups, the accuracy of Fibroscans detection of liver fibrosis was judged. Non-alcoholic fatty liver patients were taken as the study group two and hepatitis B surface antigen carriers were taken as the control group.The accuracy of Fibroscan for detecting the degree of liver steatosis was compared by comparing the liver fat controlled attenuation parameter(CAP)value between the two groups.Results There were 1 026 cases of HBsAg carriers, 83 cases of liver cirrhosis and 632 cases of non-alcoholic fatty liver.When the critical value of E was 7.3 kPa, there was a significant difference in the positive rate between the two groups(study group one 98.80% vs control group two 9.73%,P=0.000); When the critical value of E was 9.7, there was a significant difference in the positive rate between the two groups(study group one 98.80% vs control group 11.01%,P=0.000); When the critical value of E was 12.4, there was a significant difference in the positive rate between the two groups(study group one 96.39% vs control group 4.87%,P=0.000); When the critical value of E was 17.5, there was a significant difference in the positive rate between the two groups(study group one 93.98% vs control group 1.85%,P=0.000).The median of E value in study group one was 26.30 kPa.The median of E value in control group was 6.10 kPa.The value between the two groups had statistically significant differences(P=0.000).When the critical value of CAP was 237.7 dB/m,the positive rate of study group two was 92.72%, and the positive rate of control group was 31.68%.The median value of CAP in study group two was 293 dB/m.The median of CAP value of control group was 212 dB/m.The average value between the two groups had statistically significant differences(P=0.000).Conclusion Fibroscan is of great value in detecting the degree of liver fibrosis and the degree of hepatic steatosis.

參考文獻(xiàn)/References:

[1] Jung K S, Kim S U.Clinical applications of transient elastography[J].Clinical and molecular hepatology,2012,18(2): 163-173.
[2] Brener S.Transient elastography for assessment of liver fibrosis and steatosis: an evidence-based analysis[J].Ont Health Technol Assess Ser, 2015,15(18):1-45.
[3] Lai-Hung W G.Update of liver fibrosis and steatosis with transient elastography(Fibroscan)[J].Gastroenterology Report,2013,1(1):19-26.
[4] Vuppalanchi R, Sanyal A J.Myths and mysteries about staging hepatic fibrosis by fibroscan[J].Clin Gastroenterol Hepatol,2015,13(4):780-782.
[5] Shen F, Zheng R D, Mi Y Q, et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World Journal of Gastroenterology,2014,20(16):4702-4711.
[6] Vuppalanchi R, Siddiqui M S, Van Natta M L, et al.Performance characteristics of vibration-controlled transient elasto-graphy for evaluation of nonalcoholic fatty liver disease[J].Hepatology,2018,67(1):134-144.
[7] 宋樂(lè),江曉靜.瞬時(shí)彈性檢測(cè)技術(shù)在肝臟疾病診斷中的應(yīng)用[J].實(shí)用肝臟病雜志,2016,19(1):105-108.
[8] Guo L, Zheng L, Hu L, et al.Transient elastography(FibroScan)performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients[J].Med Sci Monit,2017,23:5106-5112.
[9] 中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì),中華醫(yī)學(xué)會(huì)感染病分會(huì).慢性乙型肝炎防治指南(2010年版)[J].中華肝臟病雜志,2010,19(1):13-24.
[10] 陳灝珠,鐘南山.內(nèi)科學(xué) [M].第8版.北京:人民衛(wèi)生出版社,2013:419-428.
[11] 中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)脂肪肝和酒精性肝病學(xué)組.非酒精性脂肪性肝病診療指南(2010年修訂版)[J].中華肝臟病雜志,2010,18(3):163-166.
[12] Lai-Hung W G.Prediction of fibrosis progression in chronic viral hepatitis[J].Clinical and Molecular Hepatology, 2014,20(3):228-236.
[13] Lu F M, Zhuang H.Management of hepatitis B in China[J].Chin Med J,2009,122(001): 3-4.
[14] Jia J, Hou J, Ding H,et al.Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B[J].Journal of Gastroenterology and Hepatology,2015,30(4):756-762.
[15] 武永萍,魏占芳,石栓柱,等.瞬時(shí)彈性超聲成像在評(píng)價(jià)乙型肝炎肝纖維化嚴(yán)重程度中的價(jià)值[J].肝臟,2019,24(8):905-907.
[16] G?bel T, Schadewaldt-Tümmers J, Greiner L, et al.Transient elastography improves detection of liver cirrhosis compared to routine screening tests[J].World Journal of Gastroenterology, 2015,21(3):953-960.
[17] 秦敏.慢性乙型肝炎肝硬化FibroScan測(cè)量結(jié)果與肝穿刺病理的關(guān)系[J].肝臟,2019,24(6):674-676.
[18] Fan J G, Farrell G C.Epidemiology of non-alcoholic fatty liver disease in China[J].J Hepatol,2009,50(1): 204-210.
[19] 吳惠敏,華靜.受控衰減參數(shù)在評(píng)估肝臟脂肪變性中的應(yīng)用[J].國(guó)際消化病雜志,2018,38(6):353-356.
[20] Baumeler S,Jochum W, Neuweiler J, et al.Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience[J].Swiss Med Wkly, 2019,149:w20077.
[21] 陳建能,陳愛萍,潘勤,等.FibroScan實(shí)施受控衰減參數(shù)檢測(cè)肝脂肪變的影響因素及應(yīng)用價(jià)值分析[J].肝臟,2016,21(10):805-809.

相似文獻(xiàn)/References:

[1]方主亭 唐 儀 吳少杰 周艷峰 楊厚林 陳良生 蔡森林 何劍鋒.經(jīng)頸靜脈肝內(nèi)門體分流術(shù)治療肝硬化頑固性腹水8例[J].福建醫(yī)藥雜志,2019,41(02):13.
　FANG Zhuting,TANG Yi,WU Shaojie,et al.Application of transjugular intrahepatic portosystemic shunt in cirrhotic patients with refractory ascites[J].FUJIAN MEDICAL JOURNAL,2019,41(02):13.
[2]林雪燕,黃胡萍,林志輝.特利加壓素治療肝硬化食管胃靜脈曲張出血期間血鈉下降的影響因素分析[J].福建醫(yī)藥雜志,2022,44(03):26.

備注/Memo

備注/Memo:
基金項(xiàng)目:2018年福州市衛(wèi)計(jì)系統(tǒng)創(chuàng)新團(tuán)隊(duì)培育項(xiàng)目(2018-S-wt5)1 通信作者,Email:[email protected]
更新日期/Last Update: 2020-04-15